|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reck M, Popat S, Reinmuth N, De Ruysscher
D, Kerr KM and Peters S; ESMO Guidelines Working Group: Metastatic
non-small-cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25(Suppl 3): iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pirker R, Wiesenberger K, Pohl G and Minar
W: Anemia in lung cancer: Clinical impact and management. Clin Lung
Cancer. 5:90–97. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Caro JJ, Salas M, Ward A and Goss G:
Anemia as an independent prognostic factor for survival in patients
with cancer: A systemic, quantitative review. Cancer. 91:2214–2221.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gilreath JA, Stenehjem DD and Rodgers GM:
Diagnosis and treatment of cancer-related anemia. Am J Hematol.
89:203–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Crawford J, Demetri GD, Gabrilove JL,
Blasi MV, Sarokhan BJ and Glaspy J: Clinical benefits of epoetin
alfa therapy in patients with lung cancer. Clin Lung Cancer.
3:180–190. 2002. View Article : Google Scholar
|
|
7
|
Rizzo JD, Brouwers M, Hurley P, Seidenfeld
J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode
MJ, et al American Society of Hematology and the American Society
of Clinical Oncology Practice Guideline Update Committee: American
Society of Hematology/American Society of Clinical Oncology
clinical practice guideline update on the use of epoetin and
darbepoetin in adult patients with cancer. Blood. 116:4045–4059.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jelkmann W, Bohlius J, Hallek M and
Sytkowski AJ: The erythropoietin receptor in normal and cancer
tissues. Crit Rev Oncol Hematol. 67:39–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sinclair AM, Todd MD, Forsythe K, Knox SJ,
Elliott S and Begley CG: Expression and function of erythropoietin
receptors in tumors: Implications for the use of
erythropoiesis-stimulating agents in cancer patients. Cancer.
110:477–488. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Szenajch J, Wcislo G, Jeong JY, Szczylik C
and Feldman L: The role of erythropoietin and its receptor in
growth, survival and therapeutic response of human tumor cells:
From clinic to bench - a critical review. Biochim Biophys Acta.
1806:82–95. 2010.PubMed/NCBI
|
|
11
|
Wright JR, Ung YC, Julian JA, Pritchard
KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L,
et al: Randomized, double-blind, placebo-controlled trial of
erythropoietin in non-small-cell lung cancer with disease-related
anemia. J Clin Oncol. 25:1027–1032. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bohlius J, Schmidlin K, Brillant C,
Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart
O, Kluge S, et al: Recombinant human erythropoiesis-stimulating
agents and mortality in patients with cancer: A meta-analysis of
randomised trials. Lancet. 373:1532–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rizzo JD, Somerfield MR, Hagerty KL,
Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode
MJ, Jakubowski AA, et al: Use of epoetin and darbepoetin in
patients with cancer: 2007 American Society of Hematology/American
Society of Clinical Oncology clinical practice guideline update.
Blood. 111:25–41. 2008. View Article : Google Scholar
|
|
14
|
Rodgers GM III, Becker PS, Blinder M,
Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B,
Gilreath JA, Kraut EH, et al: Cancer- and chemotherapy-induced
anemia (Version 1.2018). J Natl Compr Canc Netw. 10:628–653. 2017.
View Article : Google Scholar
|
|
15
|
Osterborg A, Aapro M, Cornes P, Haselbeck
A, Hayward CR and Jelkmann W: Preclinical studies of erythropoietin
receptor expression in tumour cells: Impact on clinical use of
erythropoietic proteins to correct cancer-related anaemia. Eur J
Cancer. 43:510–519. 2007. View Article : Google Scholar
|
|
16
|
Westenfelder C and Baranowski RL:
Erythropoietin stimulates proliferation of human renal carcinoma
cells. Kidney Int. 58:647–657. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feldman L, Wang Y, Rhim JS, Bhattacharya
N, Loda M and Sytkowski AJ: Erythropoietin stimulates growth and
STAT5 phosphorylation in human prostate epithelial and prostate
cancer cells. Prostate. 66:135–145. 2006. View Article : Google Scholar
|
|
18
|
Acs G, Chen M, Xu X, Acs P, Verma A and
Koch CJ: Autocrine erythropoietin signaling inhibits
hypoxia-induced apoptosis in human breast carcinoma cells. Cancer
Lett. 214:243–251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dolznig H, Habermann B, Stangl K, Deiner
EM, Moriggl R, Beug H and Müllner EW: Apoptosis protection by the
Epo target Bcl-XL allows factor-independent
differentiation of primary erythroblasts. Curr Biol. 12:1076–1085.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y,
Rabbani ZN, Vujaskovic Z, Dewhirst MW and Arcasoy MO:
Erythropoietin blockade inhibits the induction of tumor
angiogenesis and progression. PLoS One. 2:e5492007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Batra S, Perelman N, Luck LR, Shimada H
and Malik P: Pediatric tumor cells express erythropoietin and a
functional erythropoietin receptor that promotes angiogenesis and
tumor cell survival. Lab Invest. 83:1477–1487. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dagnon K, Pacary E, Commo F, Antoine M,
Bernaudin M, Bernaudin JF and Callard P: Expression of
erythropoietin and erythropoietin receptor in non-small cell lung
carcinomas. Clin Cancer Res. 11:993–999. 2005.PubMed/NCBI
|
|
23
|
Dunlop EA, Percy MJ, Boland MP, Maxwell AP
and Lappin TR: Induction of signalling in non-erythroid cells by
pharmacological levels of erythropoietin. Neurodegener Dis.
3:94–100. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vaupel P and Harrison L: Tumor hypoxia:
Causative factors, compensatory mechanisms, and cellular response.
Oncologist. 9(Suppl 5): 4–9. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jelkmann W: Regulation of erythropoietin
production. J Physiol. 589:1251–1258. 2011. View Article : Google Scholar :
|
|
26
|
Wohlkoenig C, Leithner K, Deutsch A,
Hrzenjak A, Olschewski A and Olschewski H: Hypoxia-induced
cisplatin resistance is reversible and growth rate independent in
lung cancer cells. Cancer Lett. 308:134–143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Komatsu N, Yamamoto M, Fujita H, Miwa A,
Hatake K, Endo T, Okano H, Katsube T, Fukumaki Y, Sassa S, et al:
Establishment and characterization of an erythropoietin-dependent
subline, UT-7/Epo, derived from human leukemia cell line, UT-7.
Blood. 82:456–464. 1993.PubMed/NCBI
|
|
28
|
Erickson-Miller CL, Pelus LM and Lord KA:
Signaling induced by erythropoietin and stem cell factor in
UT-7/Epo cells: Transient versus sustained proliferation. Stem
Cells. 18:366–373. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Belenkov AI, Shenouda G, Rizhevskaya E,
Cournoyer D, Belzile JP, Souhami L, Devic S and Chow TY:
Erythropoietin induces cancer cell resistance to ionizing radiation
and to cisplatin. Mol Cancer Ther. 3:1525–1532. 2004.
|
|
31
|
Gormley PE, Bull JM, LeRoy AF and Cysyk R:
Kinetics of cisdichlorodiammineplatinum. Clin Pharmacol Ther.
25:351–357. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Himmelstein KJ, Patton TF, Belt RJ, Taylor
S, Repta AJ and Sternson LA: Clinical kinetics on intact cisplatin
and some related species. Clin Pharmacol Ther. 29:658–664. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Elliott S, Busse L, Bass MB, Lu H, Sarosi
I, Sinclair AM, Spahr C, Um M, Van G and Begley CG: Anti-Epo
receptor antibodies do not predict Epo receptor expression. Blood.
107:1892–1895. 2006. View Article : Google Scholar
|
|
34
|
Swift S, Ellison AR, Kassner P, McCaffery
I, Rossi J, Sinclair AM, Begley CG and Elliott S: Absence of
functional EpoR expression in human tumor cell lines. Blood.
115:4254–4263. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vaupel P: Hypoxia and aggressive tumor
phenotype: Implications for therapy and prognosis. Oncologist.
13(Suppl 3): 21–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hadland BK and Longmore GD:
Erythroid-stimulating agents in cancer therapy: Potential dangers
and biologic mechanisms. J Clin Oncol. 27:4217–4226. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Neumann D, Wikström L, Watowich SS and
Lodish HF: Intermediates in degradation of the erythropoietin
receptor accumulate and are degraded in lysosomes. J Biol Chem.
268:13639–13649. 1993.PubMed/NCBI
|
|
38
|
Becker V, Schilling M, Bachmann J, Baumann
U, Raue A, Maiwald T, Timmer J and Klingmüller U: Covering a broad
dynamic range: Information processing at the erythropoietin
receptor. Science. 328:1404–1408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brown WM, Maxwell P, Graham AN, Yakkundi
A, Dunlop EA, Shi Z, Johnston PG and Lappin TR: Erythropoietin
receptor expression in non-small cell lung carcinoma: A question of
antibody specificity. Stem Cells. 25:718–722. 2007. View Article : Google Scholar
|
|
40
|
Westphal G, Niederberger E, Blum C,
Wollman Y, Knoch TA, Rebel W, Debus J and Friedrich E:
Erythropoietin and G-CSF receptors in human tumor cells: Expression
and aspects regarding functionality. Tumori. 88:150–159.
2002.PubMed/NCBI
|
|
41
|
Kumar SM, Yu H, Fong D, Acs G and Xu X:
Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway
in human melanoma cells. Melanoma Res. 16:275–283. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lester RD, Jo M, Campana WM and Gonias SL:
Erythropoietin promotes MCF-7 breast cancer cell migration by an
ERK/ mitogen-activated protein kinase-dependent pathway and is
primarily responsible for the increase in migration observed in
hypoxia. J Biol Chem. 280:39273–39277. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yasuda Y, Fujita Y, Matsuo T, Koinuma S,
Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, et al:
Erythropoietin regulates tumour growth of human malignancies.
Carcinogenesis. 24:1021–1029. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu
X and Acs G: RNA interference-mediated inhibition of erythropoietin
receptor expression suppresses tumor growth and invasiveness in
A2780 human ovarian carcinoma cells. Am J Pathol. 174:1504–1514.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yoon YK, Kim HP, Han SW, Oh DY, Im SA,
Bang YJ and Kim TY: KRAS mutant lung cancer cells are
differentially responsive to MEK inhibitor due to AKT or STAT3
activation: Implication for combinatorial approach. Mol Carcinog.
49:353–362. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Valenzuela DM and Groffen J: Four human
carcinoma cell lines with novel mutations in position 12 of c-K-ras
oncogene. Nucleic Acids Res. 14:843–852. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Acs G, Zhang PJ, McGrath CM, Acs P,
McBroom J, Mohyeldin A, Liu S, Lu H and Verma A: Hypoxia-inducible
erythropoietin signaling in squamous dysplasia and squamous cell
carcinoma of the uterine cervix and its potential role in cervical
carcinogenesis and tumor progression. Am J Pathol. 162:1789–1806.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pajonk F, Weil A, Sommer A, Suwinski R and
Henke M: The erythropoietin-receptor pathway modulates survival of
cancer cells. Oncogene. 23:8987–8991. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hardee ME, Arcasoy MO, Blackwell KL,
Kirkpatrick JP and Dewhirst MW: Erythropoietin biology in cancer.
Clin Cancer Res. 12:332–339. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Berdel WE, Danhauser-Riedl S, Oberberg D
and Zafferani M: Effects of hematopoietic growth factors on
malignant nonhematopoietic cells. Semin Oncol. 19(Suppl 4): 41–45.
1992.PubMed/NCBI
|
|
51
|
Berdel WE, Oberberg D, Reufi B and Thiel
E: Studies on the role of recombinant human erythropoietin in the
growth regulation of human nonhematopoietic tumor cells in vitro.
Ann Hematol. 63:5–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu WM, Powles T, Shamash J, Propper D,
Oliver T and Joel S: Effect of haemopoietic growth factors on
cancer cell lines and their role in chemosensitivity. Oncogene.
23:981–990. 2004. View Article : Google Scholar
|
|
53
|
Mundt D, Berger MR and Bode G: Effect of
recombinant human erythropoietin on the growth of human tumor cell
lines in vitro. Micro-titertec-tetrazolium assay.
Arzneimittelforschung. 42:92–95. 1992.PubMed/NCBI
|
|
54
|
Rosti V, Pedrazzoli P, Ponchio L, Zibera
C, Novella A, Lucotti C, Della Cuna GR and Cazzola M: Effect of
recombinant human erythropoietin on hematopoietic and
non-hematopoietic malignant cell growth in vitro. Haematologica.
78:208–212. 1993.PubMed/NCBI
|
|
55
|
Rössler J, Stolze I, Frede S, Freitag P,
Schweigerer L, Havers W and Fandrey J: Hypoxia-induced
erythropoietin expression in human neuroblastoma requires a
methylation free HIF-1 binding site. J Cell Biochem. 93:153–161.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gewirtz DA, Di X, Walker TD and Sawyer ST:
Erythropoietin fails to interfere with the antiproliferative and
cytotoxic effects of antitumor drugs. Clin Cancer Res.
12:2232–2238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Rosti V, Pedrazzoli P, Ponchio L, Zibera
C, Novella A, Lucotti C, Della Cuna GR and Cazzola M: Effect of
recombinant human erythropoietin on hematopoietic and
non-hematopoietic malignant cell growth in vitro. Haematologica.
78:208–212. 1993.PubMed/NCBI
|
|
58
|
Fischer C, Leithner K, Wohlkoenig C,
Quehenberger F, Bertsch A, Olschewski A, Olschewski H and Hrzenjak
A: Panobinostat reduces hypoxia-induced cisplatin resistance of
non-small cell lung carcinoma cells via HIF-1α destabilization. Mol
Cancer. 14:42015. View Article : Google Scholar
|
|
59
|
Gerlach MM, Merz F, Wichmann G, Kubick C,
Wittekind C, Lordick F, Dietz A and Bechmann I: Slice cultures from
head and neck squamous cell carcinoma: A novel test system for drug
susceptibility and mechanisms of resistance. Br J Cancer.
110:479–488. 2014. View Article : Google Scholar :
|
|
60
|
Koerfer J, Kallendrusch S, Merz F,
Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gaßler
N, Schopow N, et al: Organotypic slice cultures of human gastric
and esophago-gastric junction cancer. Cancer Med. 5:1444–1453.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Merz L, Höbel S, Kallendrusch S, Ewe A,
Bechmann I, Franke H, Merz F and Aigner A: Tumor tissue slice
cultures as a platform for analyzing tissue-penetration and
biological activities of nanoparticles. Eur J Pharm Biopharm.
112:45–50. 2017. View Article : Google Scholar
|
